About Bio-Path (NASDAQ:BPTH)
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357
Debt
Debt-to-Equity RatioN/A
Current Ratio9.41%
Quick Ratio9.41%
Price-To-Earnings
Trailing P/E Ratio-2.34
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales530.15
Cash FlowN/A
Price / CashN/A
Book Value$0.71 per share
Price / Book2.63
Profitability
EPS (Most Recent Fiscal Year)($0.80)
Net Income$-7,020,000.00
Net MarginsN/A
Return on Equity-83.65%
Return on Assets-73.90%
Miscellaneous
Employees9
Outstanding Shares11,340,000
Bio-Path (NASDAQ:BPTH) Frequently Asked Questions
What is Bio-Path's stock symbol?
Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."
When did Bio-Path's stock split? How did Bio-Path's stock split work?
Bio-Path shares reverse split before market open on Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.
How were Bio-Path's earnings last quarter?
Bio-Path Holdings (NASDAQ:BPTH) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). View Bio-Path's Earnings History.
What price target have analysts set for BPTH?
1 brokers have issued 12-month price targets for Bio-Path's stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Bio-Path's stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Bio-Path.
Who are some of Bio-Path's key competitors?
Some companies that are related to Bio-Path include IntelGenx Technologies (IGXT), Vivus (VVUS), Celsion (CLSN), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), PLx Pharma (PLXP), Chiasma (CHMA), Edge Therapeutics (EDGE), Lipocine (LPCN), Egalet (EGLT), OvaScience (OVAS), Kitov Pharma (KTOV), Pernix Therapeutics (PTX), Jaguar Health (JAGX), Innovus Pharmaceuticals (INNV), AEterna Zentaris (AEZS), Concordia International (CXRX) and Tonix Pharmaceuticals (TNXP).
Who are Bio-Path's key executives?
Bio-Path's management team includes the folowing people:
- Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 69)
- Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 62)
- Mr. Anthony Price MBA, Director of Fin. and Accounting
- Dr. Ana Tari Ashizawa Ph.D., MBA, Director of Research
- Dr. Suzanne Kennedy Ph.D., Director of Corp. Devel.
Has Bio-Path been receiving favorable news coverage?
Press coverage about BPTH stock has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bio-Path earned a daily sentiment score of 0.20 on Accern's scale. They also assigned press coverage about the company an impact score of 45.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Bio-Path?
Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Path's stock price today?
One share of BPTH stock can currently be purchased for approximately $1.87.
How big of a company is Bio-Path?
Bio-Path has a market capitalization of $21.21 million and generates $40,000.00 in revenue each year. The company earns $-7,020,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Bio-Path employs 9 workers across the globe.
How can I contact Bio-Path?
Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]
MarketBeat Community Rating for Bio-Path (BPTH)
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bio-Path (NASDAQ:BPTH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Bio-Path in the last 12 months. Their average twelve-month price target is $15.00, suggesting that the stock has a possible upside of 702.14%. The high price target for BPTH is $15.00 and the low price target for BPTH is $15.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.00 | $17.50 | $17.50 | $35.00 |
| Price Target Upside: | 702.14% upside | 464.52% upside | 464.52% upside | 1,066.67% upside |
Bio-Path (NASDAQ:BPTH) Consensus Price Target History
Bio-Path (NASDAQ:BPTH) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/13/2017 | HC Wainwright | Reiterated Rating | Buy -> Buy | $45.00 -> $15.00 | N/A |  |
| 4/5/2017 | Maxim Group | Set Price Target | Buy | $20.00 | High | |
| 8/11/2016 | Rodman & Renshaw | Set Price Target | Buy | $50.00 | N/A | |
(Data available from 4/22/2016 forward)
Bio-Path (NASDAQ:BPTH) Earnings History and Estimates Chart
Bio-Path (NASDAQ BPTH) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | Q3 2017 | ($0.20) | ($0.20) | | | View | N/A | |
| 8/10/2017 | Q2 2017 | ($0.20) | ($0.30) | | | View | Listen | |
| 5/11/2017 | Q1 2017 | ($0.20) | ($0.10) | | | View | N/A | |
| 3/15/2017 | 12/31/2016 | ($0.30) | ($0.10) | | $0.01 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.20) | ($0.20) | $2.50 million | | View | Listen | |
| 8/9/2016 | Q2 | ($0.20) | ($0.20) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.10) | ($0.20) | $2.33 million | | View | Listen | |
| 3/16/2016 | Q4 | ($0.10) | ($0.20) | | $1.46 million | View | N/A | |
| 11/10/2015 | Q315 | | ($0.20) | | | View | N/A | |
| 8/11/2015 | Q2 2015 | ($0.30) | ($0.10) | | | View | N/A | |
| 5/12/2015 | Q1 2015 | | ($0.20) | | | View | N/A | |
| 3/17/2015 | Q4 2014 | $0.10 | ($0.20) | | | View | N/A | |
| 11/17/2014 | Q3 2014 | ($0.10) | ($0.10) | | | View | N/A | |
| 8/18/2014 | Q214 | ($0.10) | ($0.10) | | | View | N/A | |
| 5/16/2014 | Q1 2014 | ($0.10) | ($0.10) | | | View | N/A | |
| 4/2/2014 | | $0.10 | $0.10 | | | View | N/A | |
| 11/15/2013 | Q3 2013 | ($0.10) | ($0.20) | | | View | N/A | |
| 8/15/2013 | Q2 2013 | ($0.10) | ($0.10) | | | View | N/A | |
| 5/16/2013 | Q1 2013 | ($0.10) | ($0.10) | | | View | N/A | |
| 11/16/2012 | Q3 2012 | ($0.10) | ($0.10) | | | View | N/A | |
| 8/16/2012 | Q2 2012 | ($0.10) | ($0.10) | | | View | N/A | |
| 5/17/2012 | Q1 2012 | ($0.10) | ($0.10) | | | View | N/A | |
| 4/3/2012 | Q4 2011 | | ($0.10) | | | View | N/A | |
| 11/15/2011 | Q3 2011 | ($0.20) | ($0.10) | | | View | N/A | |
| 8/15/2011 | Q2 2011 | ($0.10) | ($0.10) | | | View | N/A | |
| 5/17/2011 | Q1 2011 | ($0.20) | ($0.10) | | | View | N/A | |
| 3/31/2011 | Q4 2010 | ($0.10) | ($0.10) | | | View | N/A | |
| 11/15/2010 | Q3 2010 | | ($0.10) | | | View | N/A | |
| 8/17/2010 | Q2 2010 | | ($0.10) | | | View | N/A | |
| 4/3/2009 | Q4 2008 | | ($0.50) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Bio-Path (NASDAQ:BPTH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bio-Path (NASDAQ BPTH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.20%
Bio-Path (NASDAQ BPTH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/13/2015 | Michael J Garrison | Director | Buy | 7,343 | $1.22 | $8,958.46 | | |
| 7/9/2015 | Michael J Garrison | Director | Buy | 8,724 | $1.17 | $10,207.08 | | |
| 7/8/2015 | Michael J Garrison | Director | Buy | 60,000 | $1.19 | $71,400.00 | | |
(Data available from 1/1/2013 forward)
Bio-Path (NASDAQ BPTH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Bio-Path (BPTH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 19 at 11:20 PM |
 | Mid-Day Market Update: Sears Hometown and Outlet Stores Falls Following Q4 Results; Bio-Path Shares Surge
www.benzinga.com - April 19 at 4:13 PM |
 | Form 8-K BIO-PATH HOLDINGS INC For: Apr 18
www.streetinsider.com - April 19 at 10:08 AM |
 | Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic ...
www.globenewswire.com - April 18 at 4:07 PM |
 | Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 4:07 PM |
 | Mid-Day Market Update: Dow Gains Over 200 Points; Enphase Energy Shares Plunge
www.nasdaq.com - April 3 at 4:12 PM |
 | Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - April 3 at 4:12 PM |
 | Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today
investorplace.com - April 3 at 12:15 PM |
| ETF Report: ETFs, Futures Open in Positive Territory, Higher As Trade War Fears Subside
www.nasdaq.com - April 3 at 10:18 AM |
| US Stocks Poised for Rebound After Big Selloff
www.nasdaq.com - April 3 at 10:18 AM |
| Bio-Path Holdings Announces Publication in The Lancet Haematology
finance.yahoo.com - March 29 at 10:30 AM |
| Bio-Path (BPTH) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 8:10 PM |
| Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting
finance.yahoo.com - March 15 at 10:52 AM |
| Bio-Path Holdings to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 10:18 AM |
| Bio-Path (BPTH) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:14 AM |
| Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - February 14 at 1:08 AM |
| Bio-Path Holdings Inc (BPTH) Sees Large Decrease in Short Interest
www.americanbankingnews.com - February 11 at 1:52 AM |
| Bio-Path Holdings (BPTH) Announces 1-for-10 Reverse Stock Split
www.streetinsider.com - February 10 at 6:07 AM |
| Bio-Path Holdings Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - February 9 at 3:27 PM |
| Bio-Path Holdings to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:52 AM |
| Bio-Path Holdings Appoints Paul Aubert to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:20 PM |
| Bio-Path Holdings Appoints Paul Aubert to its Board of Directors
finance.yahoo.com - February 5 at 3:20 PM |
 | Pre-Market Technical Scan on Drug Delivery Equities -- Bio-Path, Alkermes, PetMed Express, and Valeant Pharma - PR Newswire (press release)
www.prnewswire.com - February 1 at 3:20 PM |
| Analyzing Merrimack Pharmaceuticals (MACK) & Bio-Path (BPTH)
www.americanbankingnews.com - January 25 at 3:14 PM |
| Form 8-K BIO-PATH HOLDINGS INC For: Dec 29 - StreetInsider.com
www.streetinsider.com - January 3 at 12:03 AM |
| HC Wainwright Reaffirms "Buy" Rating for Bio-Path (BPTH)
www.americanbankingnews.com - December 31 at 3:38 PM |
| Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook
finance.yahoo.com - December 29 at 5:27 PM |
| -$0.02 Earnings Per Share Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - December 25 at 1:16 PM |
| Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 27 at 5:22 PM |
| Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - November 20 at 1:28 AM |
| Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at
www.americanbankingnews.com - November 19 at 4:20 PM |
| Bio-Path Holdings, Inc. (BPTH) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 10 at 12:51 PM |
| Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
finance.yahoo.com - November 10 at 12:41 PM |
| Bio-Path Holdings Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:52 PM |
| Bio-Path reports 3Q loss
finance.yahoo.com - November 9 at 5:52 PM |
| Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:29 AM |
| Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts
finance.yahoo.com - November 6 at 5:51 PM |
| Bio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and Warrants
www.streetinsider.com - November 3 at 5:20 PM |
| Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering
finance.yahoo.com - November 3 at 5:20 PM |
| Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017
finance.yahoo.com - November 3 at 8:25 AM |
| Bio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM |
| Bio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial Comparison
www.americanbankingnews.com - October 30 at 9:28 AM |
| Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
finance.yahoo.com - October 23 at 4:37 PM |
| Is It Time To Buy Bio-Path Holdings Inc (BPTH)?
finance.yahoo.com - October 11 at 6:11 PM |
| Bio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - October 11 at 12:20 PM |
| Bio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM |
| Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM |
| Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM |
| -$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM |
| Bio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM |
Bio-Path (NASDAQ:BPTH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bio-Path (NASDAQ:BPTH) Income Statement, Balance Sheet and Cash Flow Statement
Bio-Path (NASDAQ BPTH) Stock Chart for Sunday, April, 22, 2018
Loading chart…
